<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903132</url>
  </required_header>
  <id_info>
    <org_study_id>20-011877</org_study_id>
    <nct_id>NCT04903132</nct_id>
  </id_info>
  <brief_title>Cellular Senescence and COVID-19 Long-Hauler Syndrome</brief_title>
  <official_title>Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if senescent cells and their secretome contribute to&#xD;
      Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate&#xD;
      senescent cells, should be initiated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors</measure>
    <time_frame>6 months</time_frame>
    <description>If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.</description>
  </primary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must be at least 18 years or older, have a positive PCR or antibody test within&#xD;
        six months, and report any ongoing symptoms associated with Post-COVID or Long-Haulers&#xD;
        Syndrome.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent or LAR.&#xD;
&#xD;
          -  At least 18 years old.&#xD;
&#xD;
          -  Ability of subject or LAR to read and speak the English language.&#xD;
&#xD;
          -  Positive PCR or antibody test within 12 months of initial study visit.&#xD;
&#xD;
          -  Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler&#xD;
             Syndrome.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any potential participant who refuses medical record review.&#xD;
&#xD;
          -  Pregnant females.&#xD;
&#xD;
          -  Incarcerated individuals.&#xD;
&#xD;
          -  Inability to cooperate or any medical condition that, in the opinion of the&#xD;
             investigator, interferes with the evaluation of the study objectives or increases the&#xD;
             subject's risk by participating in the study.&#xD;
&#xD;
          -  Patient is unfit to participate at the discretion of the Principal Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

